Publication | Closed Access
Phase I Study of GRN1005 in Recurrent Malignant Glioma
177
Citations
37
References
2013
Year
GRN1005 delivers paclitaxel across the BBB and achieves therapeutic concentrations in tumor tissue. It has similar toxicity to paclitaxel and appears to have activity in recurrent glioma. The recommended phase II dose is 650 mg/m(2) every 3 weeks.
| Year | Citations | |
|---|---|---|
Page 1
Page 1